Westside Animal Hospital

Patient Chart

42052 North 50th Street West Quartz Hill, CA 93536 661-943-0303

Printed: 06-25-24 at 12:16p

CLIENT INFORMATION

Name OMAR VON MULLER (2442) Address 4568 WEST AVE. M14

Quartz Hill, CA 93536

Phone 661 365-7993 **Balance** 0.00

PATIENT INFORMATION

Name STELLA 2 Species Canine

Sex Female, Spayed Breed Bulldog, French

Birthday 07-15-17 **Age** 6y

ID Rabies 000139009
Color Brown and White Weight 20.00 lbs

Reminded 05-31-24 Codes

MEDICAL HISTORY

Date	Ву	Code	Description	Qty (Variance)	Amount
06-24-24	СН	ANTREQ EP 210	Antech Requisition 11975-AVI1781 OV/Consult	25	60.00

ASSESSMENT:

::Exam

::Surgical Drop-Off

Quiet but responsive; Wt. 20 lbs;T-102.1; CRT-1.2" Chest Aus - wnl; No C/S; HR-125;RR- 16;BP-127/72

Abd. Palp - wnl; Good Appetite; No V/D

Otic/Ocular/Oral - wnl No Neurological Deficits No Dermatological Issues

A. 2-3 cm Dermal Mass distal to previous incision site

B. Soft Tissue Mass Right Axillary area Owner wants them removed and biopsied.

Iso/O2 induced and maintained

Baytril 1.0 ml. IM Atropine Inj. 1.0 ml IM

CP Monitor

Prep surgical sites; Excised masses; Note: Underlying tissues on both sites are severely bruised for

reason unknown.

SQ 3/0 Vicryl; Skin 2/0 Ethilon

Uneventful recovery

Rec. E.Collar to protect incision sites

Apply warm compress to reduce swelling and inflammation 2x/day

Re-check 2 weeks for R/S

Rx Cephalexin 250 mg #30 Give orally 1 capsule twice daily.

Rx Tramadol HCL 50 mg #15 Give orally 1 tablet twice daily for pain relief.

Page: 2

Date	Ву	Code	Description	Qty (Variance)	Amount
06-24-24	CH	AI 002	Iso/Oxy (2)		320.00
		IN 014	Atropine Sulfate Inj.		35.50
		IN 009	Baytril Inj.		45.50
		IS 654	Mass Excision Gr.2		450.00
		LO 919	Antech (FBX) Histo		380.00
		RX 135	Cephalexin 250 mg #30		16.30
	Give oally 1 capsu	ıle twice dail	у		
	Give orally 1 table	RX395 t twice daily	Tramadol HCL 50 mg #15		18.00
06-10-24	СН	EP 210	OV/Consult		60.00
	ASSESSMENT: :: Exam		C 1, C 21.10 u.i.		00.00
	non-painful		m right inguinal to axillary region	s;Right frontleg also edemat	ous;
	:: Hx.of Mast Cell	Tumor unde	r treatment with Oncologist.		
	Quiet but respons	ive; T- 101.2	; Wt. 24.5; CRT - < 1.2 secs.		
			; RR - 16/m; No C/S; Lung sound	ds - wnl	
	Abd. Palp - wnl.; (Good Appetit	e; No V/D		
	Peripheral LNs - n				
	Ambulatory on PE		ogical deficits		
	Otic/Oral/Ocular -				
	Angioedema of ur				
	• •	ainage relate	ed to Mast Cell Tumor		
	Insect Bite Trauma				
	Plan: Refer to One	cologist			
	Lasix 1.0 ml.	-			
			ve orally 1 tablet twice daily		
			d areas twice daily.		
		IN 037	Medical Waste		3.30
		IN 022	Lasix Inj. 1.0 ml IM		36.50
		RX 158	Furosemide 12.5 mg #30		30.00
	Give orally 1 table	t twice daily.			
03-20-24	СН	MHI 08	Re-Chk; R/S		
00 20 24	ASSESSMENT:	WII II OO	No onk, 100		
	::Re-Check; R/S				
	::Requesting bloo	d work and x	rays		
		IN 037	Medical Waste		3.30
		LO 958	Venipuncture		25.00
		ANTREQ	•	l177174	
		LO 968	Antech (SA 090) Senior Comp		295.00
		DP 115	X-ray Interpretation		65.00
		DP 117	X-ray 2 views		250.00
03-08-24	СН	ANTREQ	•	l177075	
		EP 210	OV/Consult		60.00

Patient Chart for STELLA 2

Re-check in 1 week

Date: 06-25-24, Time: 12:16p Page: 3

Date	Ву	Code	Description	Qty (Variance)	Amount
	ASSESSMENT: ::Exam ::Check growth o BAR; Wt. 32 lbs; Chest Aus - wnl; Abd. Palp - wnl; Ocular/Otic/Oral No neurological o No evidence of p @4 in. hemorrha Plan: Surgical ex No blood work or Owner approved.	TPR - wnl No C/S Good Appetit - wnl deficits eriperal lymp gic dermal m cision and bi Chest X-ray	e; No V/D hadenopathy ass right side of mid body opsy		
		IM; Atropine a; Excised m on sutures u			
		50 mg #30 G	vound protection ive orally 1 capsule twice daily. Give orally 1 tablet twice daily fo	or pain relief	
03-08-24	СН	IN 009 IN 014 IN 037 OR 600 AI 002 IS 654 LO 919	Baytril Inj. Atropine Sulfate Inj. Medical Waste OR Setup, General Iso/Oxy (2) Mass Excision Gr.3 Antech (FBX) Histo	3	45.50 35.50 9.90 55.00 320.00 550.00 260.00
	Give orally 1 caps	RX 135 sule twice da	Cephalexin 250 mg #30 ily.		16.30
	Give orally 1 table	RX 354 et twice daily	Tramadol HCL 50 mg tab. for pain relief.	15	18.00
03-22-23	CH ASSESSMENT: :: EXAM :: CHECK EYE	EP 210	OV/Consult		60.00
	BAR; Wt. 18 lbs; Abd. Palp wnl; Chest Aus - wnl; Ocular: OD - Eo Oral - wnl Otic - wnl Discuss tx, of eye DepoMedrol 10 n Rx Neopolydex S Instill 2 drops to r	No V/D; good No C/S sinophilic Ke e condition wing. IM busp, ight eye twic	d appetite eratitis; OS - wnl ith owner; approved.		

Patient Chart for STELLA 2

Date: 06-25-24, Time: 12:16p Page: 4

Client: OMAR VON MULLER

Ву	Code	Description	Qty (Variance)	Amount
СН	IN 037	Medical Waste		3.30
	IN 015	MethylPred Acetate Inj.		40.50
	RX 241	Neopolydex Ophth. Susp.		30.00
still 2 drops to rio	ght eye twice	e daily.		
СН	MHI 01	Vaccination Clinic		14.50
	CH still 2 drops to riç	CH IN 037 IN 015 RX 241 still 2 drops to right eye twice	CH IN 037 Medical Waste IN 015 MethylPred Acetate Inj. RX 241 Neopolydex Ophth. Susp. still 2 drops to right eye twice daily. CH MHI 01 Vaccination Clinic	CH IN 037 Medical Waste IN 015 MethylPred Acetate Inj. RX 241 Neopolydex Ophth. Susp. still 2 drops to right eye twice daily. CH MHI 01 Vaccination Clinic



800-872-1001

Patient Info:

Name: STELLA 2 Chart No:N

Owner: VON MULLER OMAR Doctor: COCO HAGOS, DVM

Species: Canine Breed: French Bulldog

COCO HAGOS, DVM

Age: 6Y Sex: SF

Doctor

Hospital:

Westside Animal Hosp 42052 N 50th St W Quartz Hill, CA 93536

Antech ID: 95219

Owner

VON MULLER OMAR

Lab:

ANTECH Diagnostics 17620 Mt. Herrmann Street Fountain Valley, CA 92708

Reported: 07/03/24 Received: 06/24/24

Pet Name STELLA 2

IRPC08519614 Histopathology

Accession No.

Source: 1) Right axillary area. 2) Right abdominal area. Good health at this time. Undergoing chemo for the mast cell tumor. The first specimen removed from right axillary area. The second specimen removed from the previous biopsied area (mast cell tumor). Previous accession (IRPC08356733) 3/8/2024, CHEST AREA: CUTANEOUS MAST CELL TUMOR, HIGH-GRADE/GRADE II, WITH ABUNDANT NECROSIS AND HEMORRHAGE, HAIRED SKIN, CHEST AREA.

-

Received: A 2.0 cm x 4.0 cm skin biopsy with a 2.0 cm x 3.0 cm mass. A 1.8 cm x 3.0 cm skin biopsy with a 2.2 cm x 2.6 cm mass.

SOURCE No. 1:

A 2.0 cm x 4.0 cm skin biopsy with a 2.0 cm x 3.0 cm mass

MICROSCOPIC FINDINGS: MASS 1: MAST CELL TUMOR, SUBCUTANEOUS, HIGH GRADE, WITH EXTENSIVE HEMORRHAGE

Negative predictive factors for survival times of subcutaneous mast cell tumors include mitotic index >4, multinucleated cells and infiltrative pattern:

Mitotic index (>4 in 10 HPF; yes/no): Yes (13/10 HPF (2.37mm2))

Multinucleated cells (yes/no): No Infiltrative pattern (yes/no): No

Surgical margins: Excision is complete based on evaluated sections.

Lateral: 2.0 mm Deep: 1.2 mm

Angiolymphatic invasion: No

COMMENTS:

There are no distinguishing identifiers (i.e. suture tags, separate containers) to differentiate between mass 1 and 2. Mass 1 (measurements above) is consistent with a mast cell tumor that is confined to the subcutis, and thus the grading scheme applied to

Doctor COCO HAGOS, DVM

Owner
VON MULLER OMAR

Pet Name STELLA 2

Histopathology

dermal tumors is not appropriate in this case. However, this tumor is histologically most consistent with a HIGH GRADE CUTANEOUS MAST CELL TUMOR.

In one study only 4% of subcutaneous mast cell tumors metastasized and the local recurrence rate was <10%, even when tumors were not completely excised. Decreased survival is associated with an increased mitotic index (>4 per ten high power fields), infiltrative growth pattern and the presence of at least one multinucleated (or binucleated) tumor cells in ten high power fields.

More aggressive biological behavior, defined as local recurrence, distant metastasis and mortality due to mast cell disease is associated with increase in cytoplasmic staining for KIT. Other prognostic markers for subcutaneous mast cell tumors include AgNOR and Ki67 expression using immunohistochemistry. In one paper, mitotic index, Ki67, and Ki67, AgNOR, and KIT cellular localization patterns were significantly associated with local recurrence and metastasis in subcutaneous mast cell tumors.

Veterinarians, for information on staging and treatment options, consultation with a clinical oncologist is recommended. If you do not have a clinical oncology specialist you work with on a routine basis, then you can contact our consultation service, at 1-800-872-1001, if you would like a consultation with one of our Board Certified Oncologists. This service is provided free of charge from Antech Diagnostics.

ADDITIONAL DIAGNOSTICS:

Additional prognostic information may help to determine the most appropriate course of action for follow up therapy. A panel of prognostic indicators (listed above) for canine mast cell tumors can be ordered through Antech. This panel can be ordered by calling CUSTOMER SERVICE and ordering the MAST CELL TUMOR PROGNOSTIC PANEL on BLOCK 1.

MICROSCOPIC DESCRIPTION:

The subcutis is expanded by a poorly demarcated, unencapsulated, poorly to moderately cellular mass composed of moderately-differentiated neoplastic mast cells admixed with few to moderate numbers of eosinophils separated by hemorrhagic resident stroma. Neoplastic cells have distinct cell borders, a moderate amount of basophilic cytoplasmic granules, a large round nucleus with clumped chromatin, a prominent nucleolus. Anisocytosis and anisokaryosis are moderate, with karyomegaly.

REFERENCES:

Thompson JJ et al. Canine subcutaneous mast cell tumor: characterization and prognostic indices. Vet Pathol. 48(1) 156-168, 2011.

Histopathology

Thompson, JJ et al. Canine subcutaneous mast cell tumors: Cellular Proliferation and KIT Expression as Prognostic Indices. Vet Path. 2011. 48(1): 169-181.

Kiupel M et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol. 48(1) 147-155, 2011.

Baginski H, Davis G, Bastian RP. The prognostic value of lymph node metastasis with grade 2 MCTs in dogs: 55 cases (2001-2010). J Am Anim Hosp Assoc. 2014;50(2):89-95.

Canine Subcutaneous Mast Cell Tumour: Diagnosis and Prognosis Journal of Comparative Pathology 136:231-239, 2007

Weishaar, KM et al. Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumour and a proposed classification system for the evaluation of node metastasis. J Comp Path. 2014; 151(4): 329-38.

SOURCE No. 2:

mass 2 (A 1.8 cm x 3.0 cm skin biopsy with a 2.2 cm x 2.6 cm mass.)

MICROSCOPIC FINDINGS: MASS 2: CUTANEOUS MAST CELL TUMOR, HIGH GRADE (2-TIER), GRADE 2 (PATNAIK)

Patnaik grade: 2

Mitotic count: >20 in 10 HPF(2.37 mm2) Angiolymphatic invasion: None identified

Narrowest histologic Margins: Excision is complete.

Lateral: 0.9 mm

Page 3 of 5

Accession No. IRPC08519614

Doctor COCO HAGOS, DVM

Owner
VON MULLER OMAR

Pet Name STELLA 2

Histopathology

Deep: 0.8 mm

COMMENTS:

Cutaneous mast cell tumors (cMCT) are one of the most common cutaneous neoplasms of dogs. Two grading systems for cMCT have been developed to give the best prognostic information. The 1984 Patnaik 3-tier grading system is more subjective and survival rate past 1500 days decreases with increased grade. Based on the Patnaik grading system, this is a Grade 2 mast cell tumor.

The two-tier grading system developed by Kiupel et al. in 2011 classifies mast cell tumors as low grade or high grade based on more objective measurements, which include numbers of mitotic figures, multinucleated cells, karyomegaly, etc. To assess the parameters, fields were selected that were the most mitotically active or had the highest degree of anisokaryosis. High-grade mast cell tumors are significantly associated with a shorter time to metastases or new tumor development and with a shorter survival time. The median survival time for high-grade mast cell tumors is less than 4 months.

More aggressive biological behavior, defined as local recurrence, distant metastasis and mortality due to mast cell disease is associated with increase in cytoplasmic staining for KIT. Other prognostic markers include AgNOR, PCNA, and Ki67 expression using immunohistochemistry, and PCR screening for c-KIT mutations.

ADDIIONAL DIAGNOSTICS:

Additional prognostic information may help to determine the most appropriate course of action for followup therapy. A panel of prognostic indicators for canine mast cell tumors can be ordered through Antech. The panel includes immunohistochemistry for KIT, PCNA, Ki67, and AgNOR; and PCR for c-KIT exons 11 and 8. This panel can be ordered by calling CUSTOMER SERVICE and ordering the MAST CELL TUMOR PROGNOSTIC PANEL (Test Code S86601) on BLOCK 4.

MICROSCOPIC DESCRIPTION:

Expanding the dermis and subcutis and elevating the is a moderately well-demarcated, unencapsulated, multilobulated, densely cellular mass composed of moderately-differentiated neoplastic mast cells admixed with eosinophils on a moderate to abundant, edematous, fibrocollagenous stroma. Mast cells have distinct cell borders, moderate amphophilic granular cytoplasm, a round nucleus with stippled chromatin, and one prominent nucleolus. Anisocytosis and anisokaryosis are moderate with karyomegaly.

REFERENCES:

Kiupel et al. Proposal of a Two-Tier Grading System for Canine Cutaneous Mast Cell Tumors to More Accurately Predict Biologic Behavior. Vet Path. 48(1) 147 - 55, 2011.

Patnaik et al. Canine Cutaneous Mast Cell Tumor: Morphologic Grading and Survival Time in 83 Dogs. Vet Path. 21:469 - 474, 1984.

Pet Name STELLA 2

Histopathology

Schultheiss, PC et al. "Association of Histologic Tumor Characteristics and Size of Surgical Margins with Clinical Outcome after Surgical Removal of Cutaneous Mast Cell Tumors in Dogs." JAVMA 238.11 (2011): 1464-469.

Webster, JD et al. Cellular Proliferation in Canine Cutaneous Mast Cell Tumors: Associations with c-KIT and Its Role in Prognostication. Veterinary Pathology. 2007. 44: 298-308.

PATHOLOGIST:

Courtney Sweeney, DVM, MS, Diplomate ACVP Anatomic Pathology

Available Sunday - Thursday (Central Time Zone)

VETERINARIANS ONLY: If you would like to discuss this case, please contact: Courtney.Sweeney@antechmail.com.

VETERINARIANS ONLY: To discuss treatment options, please contact an appropriate clinical specialist. Free consultation is available through ANTECH by calling Customer Service at 1-800-872-1001.

Note: Voice recognition software may have been used to generate portions of this report.

VETERINARIANS ONLY: Questions or concerns? Please contact your pathologist directly (see signature for hours and contact information). For non-pathology questions such as clinical advice and treatment options, Antech provides free consultations with board-certified specialists, available through Client Services (1-800-872-1001, Option 0) or via your Health Tracks account. Considering this case for presentation, publication, or research? Because this report is for clinical use only, please contact us to receive consent for non-clinical use and publication-ready images.

PET OWNERS: Please contact your veterinarian with any questions.



Old fashioned love and all the latest technology.

Veterinary Cancer Group, San Fernando Valley

20051 Ventura Boulevard, Suite I

Suite I

Woodland Hills, California, 91364

Ph: (818) 888-6882 Fax: (818) 436-0456

Email: sfv.info@vetcancergroup.com

www.vetcancergroup.com

BILL TO

Stephen Winick 11037 Santa Monica Boulevard Westwood Los Angeles, California, 90025

ACCOUNT STATEMENT

Printed: 01-10-2025 Custumor ID#: 401267

STATEMENT DATE

From: 04-09-2024 01-09-2025 To:

04-09-2024 Opening Balance -\$227.50

Patient: Stella

Date	Ref. No.	Cust. Ref.	Transaction Type	Patient	Charges	Paymen	ts Balance
04-09-2024	645427		Invoice		\$1314.61		
Quantity	Description	D	Discount	De	partment		Total
1	New Patient Review			Prir	mary Inventory S	SFV	\$26.00
1	Consult, Oncology (B	undle)		Prir	mary Inventory S	SFV	\$201.50
1	Thorax - VD			Prir	mary Inventory S	SFV	\$270.11
1	Interpretation, Radiography Outside Study		Primary inventory SEV		SFV	\$103.00	
1	OSP Ultrasound - Abd	domen		Prir	mary Inventory S	SFV	\$714.00
				Total excluding TAX	(: \$1314.61	TAX: \$0.00	Total: \$1314.61

04-10-2024	645562	Invoice	\$700.71		
Quantity	Description	Discount	Department		Total
1	Consult, Oncology Recheck	\$114.00	Primary Inventory	SFV	\$0.00
1	CBC - Heska	\$92.19	Primary Inventory	SFV	\$0.00
1	Pre-surgical Panel	\$150.00	Primary Inventory	SFV	\$0.00
1	Blood Collection, Diagnostic	\$38.96	Primary Inventory	SFV	\$0.00
1	Catheterization, Peripheral IV	\$0.00	Primary Inventory	SFV	\$118.49
0.43	Diphenhydramine Inj HCI 50mg/mL (Per mL)	\$0.00	Primary Inventory	SFV	\$35.50
0.22	Dolorex Inj 10mg/mL C-4 (Per mL)	\$0.00	Primary Inventory	SFV	\$55.24
1	Anesthesia, Induction Administration	\$0.00	Primary Inventory	SFV	\$109.74
1.4	PropoFlo 28 Inj 10mg/mL (Per mL)	\$0.00	Primary Inventory	SFV	\$45.09
20	Anesthesia, Isoflurane Admin / min	\$0.00	Primary Inventory	SFV	\$192.75
20	Anesthesia, Monitoring / min	\$0.00	Primary Inventory	SFV	\$82.60
1	Electrochemotherapy Set-Up & Admin	\$1500.00	Primary Inventory	SFV	\$0.00
1	Bleomycin Inj 15 units (Per Vial)	\$291.80	Primary Inventory	SFV	\$0.00
1	Chemotherapy Administration	\$73.63	Primary Inventory	SFV	\$0.00
1	Intralesional Administration by Doctor	\$282.07	Primary Inventory SFV		\$0.00
1	Chemo Hazardous Waste Disposal	\$42.80	Primary Inventory SFV		\$0.00
30	Gabapentin 100mg (Per Capsule)	\$0.00	Primary Inventory	SFV	\$32.42
30	Prednisone 10mg (Per Tablet)	\$0.00	Primary Inventory	SFV	\$28.88
Γ			Total excluding TAX: \$700.71	TAX: \$0.00	Total: \$700.71

05-22-2024	649116	Invoice	\$523.81	
Quantity	Description	Discount	Department	Total
1	Consult, Oncology Recheck		Primary Inventory SFV	\$114.00
1	PreOp Screen w/SDMA,CBC.UA		Primary Inventory SFV	\$225.05
1	Blood Collection, Diagnostic		Primary Inventory SFV	\$38.96
1	Cystocentesis		Primary Inventory SFV	\$43.28
1	NIBP, Diagnostic		Primary Inventory SFV	\$102.52
			Total excluding TAX: \$523.81 TAX: \$0.00	Total: \$523.81

1				
06-19-2024	651311	Invoice	\$828.00	
Quantity	Description	Discount	Department	Total
1	Consult, Oncology Recheck		Primary Inventory SFV	\$114.00
1 1	OSP Ultrasound - Abdomen		Primary Inventory SFV	\$714.00
			Total excluding TAX: \$828.00 TAX: \$0.00	Total: \$828.00
07-10-2024	652971	Invoice	\$114.00	
Quantity	Description	Discount	Department	Total
1	Consult, Oncology Recheck	Discount	Primary Inventory SFV	\$114.00
-	Consult, Oncology Recheck		Total excluding TAX: \$114.00 TAX: \$0.00	Total: \$114.00
			Total excluding TAX. \$114.00 TAX. \$0.00	10tai: \$114.00
07-24-2024	654143	Invoice	\$114.00	
Quantity	Description	Discount	Department	Total
1	Consult, Oncology Recheck		Primary Inventory SFV	\$114.00
			Total excluding TAX: \$114.00 TAX: \$0.00	Total: \$114.00
08-13-2024	655714	Invoice	\$490.96	
Quantity	Description	Discount	Department	Total
1	Consult, Oncology Recheck		Primary Inventory SFV	\$114.00
1	CBC		Primary Inventory SFV	\$111.00
1	Blood Collection, Diagnostic		Primary Inventory SFV	\$38.96
1	Vinblastine Sulfate Inj 1mg/mL 10mL		Primary Inventory SFV	\$98.00
	(Per mL) Chemotherapy Safety Closed System		· · ·	
1	(Per System)		Primary Inventory SFV	\$75.00
1	Chemo Hazardous Waste Disposal		Primary Inventory SFV	\$54.00
			Total excluding TAX: \$490.96 TAX: \$0.00	Total: \$490.96
08-20-2024	656314	Invoice	\$320.75	
Quantity	Description	Discount	Department	Total
1	Consult, Oncology Recheck		Primary Inventory SFV	\$126.00
1	CBC		Primary Inventory SFV	\$111.00
1	Blood Collection, Diagnostic		Primary Inventory SFV	\$38.96
7	Enrofloxacin 68mg		Primary Inventory SFV	\$44.79
			Total excluding TAX: \$320.75 TAX: \$0.00	Total: \$320.75
08-27-2024	656898	Invoice	\$543.31	
Quantity	Description	Discount	Department	Total
1	Consult, Oncology Recheck		Primary Inventory SFV	\$126.00
1	CBC		Primary Inventory SFV	\$111.00
1	Blood Collection, Diagnostic		Primary Inventory SFV	\$38.96
7	Enrofloxacin 68mg		Primary Inventory SFV	\$44.79
0.88	Vinblastine Sulfate Inj 1mg/mL 10mL (Per mL)		Primary Inventory SFV	\$93.56
1	Chemotherapy Safety Closed System (Per System)		Primary Inventory SFV	\$75.00
1	Chemo Hazardous Waste Disposal		Primary Inventory SFV	\$54.00
			Total excluding TAX: \$543.31 TAX: \$0.00	Total: \$543.31

09-05-2024	657719	Invoice	\$2698.76	
	Description	Discount	Department	Total
Quantity	•	Discount	·	
1	Consult, Oncology Recheck CBC		Primary Inventory SFV	\$126.00
1			Primary Inventory SFV Primary Inventory SFV	\$111.00
1	Blood Collection, Diagnostic		, ,	\$38.96
1	Pre-surgical Panel		Primary Inventory SFV	\$150.00
11	Enrofloxacin 68mg		Primary Inventory SFV	\$60.67
1	Denamarin Advanced Chewable Tablets Small/Medium Dog 30ct (Per Bottle)		Primary Inventory SFV	\$121.46
2	Gleostine 10mg (Per Capsule)		Primary Inventory SFV	\$249.04
1	Lomustine 6mg (Per Tablet)		Primary Inventory SFV	\$13.64
1	Lomustine 2.5mg (Per Capsule)		Primary Inventory SFV	\$19.24
60	Prednisone 10mg (Per Tablet)		Primary Inventory SFV	\$40.75
12	Gilvetmab pre-paid		Primary Inventory SFV	\$1740.00
_ 1	Oral Chemotherapy Handling Fee		Primary Inventory SFV	\$28.00
			Total excluding TAX: \$2688.22 TAX: \$1	0.54 Total: \$2698.76
09-11-2024	658264	Invoice	\$275.96	
Quantity	Description	Discount	Department	Total
1	Consult, Oncology Recheck		Primary Inventory SFV	\$126.00
1	CBC		Primary Inventory SFV	\$111.00
1			, ,	
-	Blood Collection, Diagnostic		Primary Inventory SFV	\$38.96
			Total excluding TAX: \$275.96 TAX: \$	0.00 Total: \$275.96
09-19-2024	658943	Invoice	\$678.46	
Quantity	Description	Discount	Department	Total
1	Consult, Oncology Recheck	\$0.00	Primary Inventory SFV	\$126.00
0.40	Diphenhydramine Inj HCI 50mg/mL (Per			
0.42	mL)	\$0.00	Primary Inventory SFV	\$43.46
6	Gilvetmab Injectable 20mg/mL (Per mL)	\$870.00	Primary Inventory SFV	\$0.00
1	CRI Set-Up	\$0.00	Primary Inventory SFV	\$455.00
1	Chemo Hazardous Waste Disposal	\$0.00	Primary Inventory SFV	\$54.00
			Total avaluding TAV, #670 46 TAV, #	
1			Total excluding TAX: \$678.46 TAX: \$	0.00 Total: \$678.46
Comments: 0	ore-paid for Gilvetmab on 9/05/2024 - JR		Total excluding TAX: \$678.46 TAX: \$1	0.00 Total: \$678.46
Comments: 0	ore-paid for Gilvetmab on 9/05/2024 - JR 659913	Invoice	\$512.49	0.00 Total: \$678.46
10-01-2024	659913		\$512.49	
10-01-2024 Quantity	659913 Description	Discount	\$512.49 Department	Total
10-01-2024	659913 Description Consult, Oncology Recheck	Discount \$0.00	\$512.49	
10-01-2024 Quantity	659913 Description	Discount \$0.00	\$512.49 Department	Total
10-01-2024 Quantity	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per	Discount \$0.00 \$0.00	\$512.49 Department Primary Inventory SFV	Total \$126.00
10-01-2024 Quantity 1 0.43	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL)	Discount \$0.00 \$0.00	\$512.49 Department Primary Inventory SFV Primary Inventory SFV	Total \$126.00 \$43.59
10-01-2024 Quantity 1 0.43	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCl 50mg/mL (Per mL)	Discount \$0.00 \$0.00 \$870.00	\$512.49 Department Primary Inventory SFV Primary Inventory SFV Primary Inventory SFV	Total \$126.00 \$43.59 \$0.00
10-01-2024 Quantity 1 0.43 6 1	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration	\$0.00 \$0.00 \$870.00 \$0.00	\$512.49 Department Primary Inventory SFV Primary Inventory SFV Primary Inventory SFV Primary Inventory SFV	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00
10-01-2024 Quantity 1 0.43 6 1 1	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal	\$0.00 \$0.00 \$870.00 \$0.00 \$0.00	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 TAX: \$6	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00
10-01-2024 Quantity 1 0.43 6 1 - 1 - 1 10-01-2024	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal	Discount \$0.00 \$0.00 \$870.00 \$0.00 \$0.00	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 -\$455.00	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00 0.00 Total: \$512.49
10-01-2024 Quantity 1 0.43 6 1 1	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal	\$0.00 \$0.00 \$870.00 \$0.00 \$0.00	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 TAX: \$6	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00
10-01-2024 Quantity 1 0.43 6 1 - 1 - 1 10-01-2024	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal	Discount \$0.00 \$0.00 \$870.00 \$0.00 \$0.00	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 -\$455.00	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00 0.00 Total: \$512.49
10-01-2024 Quantity 1 0.43 6 1 - 1 - 1 10-01-2024 Quantity - 1 - 1	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal 659981 Description CRI Set-Up	Discount \$0.00 \$0.00 \$870.00 \$0.00 \$0.00	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 -\$455.00 Department	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00 0.00 Total: \$512.49
10-01-2024 Quantity 1 0.43 6 1 - 1 - 1 10-01-2024 Quantity - 1 - 1	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal 659981 Description	Discount \$0.00 \$0.00 \$870.00 \$0.00 \$0.00	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 TAX: \$6 -\$455.00 Department Primary Inventory SFV	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00 0.00 Total: \$512.49
10-01-2024 Quantity 1 0.43 6 1 - 1 - 1 10-01-2024 Quantity - 1 - 1	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal 659981 Description CRI Set-Up	Discount \$0.00 \$0.00 \$870.00 \$0.00 \$0.00	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 TAX: \$6 -\$455.00 Department Primary Inventory SFV	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00 0.00 Total: \$512.49
10-01-2024 Quantity 1 0.43 6 1 - 1 - 1 10-01-2024 Quantity1 Comments: Cree	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal 659981 Description CRI Set-Up	Discount \$0.00 \$0.00 \$870.00 \$0.00 \$0.00 Invoice Discount	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 TAX: \$6 Department Primary Inventory SFV Total excluding TAX: -\$455.00 TAX: \$6	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00 0.00 Total: \$512.49
10-01-2024 Quantity 1 0.43 6 1 1 10-01-2024 Quantity1 Comments: Cre 10-01-2024	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal 659981 Description CRI Set-Up edit generated from invoice 658943 659976 Description	Discount \$0.00 \$0.00 \$870.00 \$0.00 Invoice Discount	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 -\$455.00 Department Primary Inventory SFV Total excluding TAX: -\$455.00 Department Primary Inventory SFV Total excluding TAX: -\$455.00 Department	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00 0.00 Total: \$512.49 Total -\$455.00 0.00 Total: -\$455.00
10-01-2024 Quantity 1 0.43 6 1 - 1 10-01-2024 Quantity -1 Comments: Cre 10-01-2024 Quantity	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal 659981 Description CRI Set-Up edit generated from invoice 658943	Discount \$0.00 \$0.00 \$870.00 \$0.00 Invoice Discount	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 -\$455.00 Department Primary Inventory SFV Total excluding TAX: -\$455.00 TAX: \$6 \$288.90 Department Primary Inventory SFV	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00 0.00 Total: \$512.49 Total -\$455.00 0.00 Total: -\$455.00
10-01-2024 Quantity 1 0.43 6 1 10-01-2024 Quantity Comments: Cre 10-01-2024 Quantity	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal 659981 Description CRI Set-Up edit generated from invoice 658943 659976 Description	Discount \$0.00 \$0.00 \$870.00 \$0.00 \$0.00 Invoice Discount Invoice Discount	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 -\$455.00 Department Primary Inventory SFV Total excluding TAX: -\$455.00 Department Primary Inventory SFV Total excluding TAX: -\$455.00 Department	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00 0.00 Total: \$512.49 Total -\$455.00 0.00 Total: -\$455.00
10-01-2024 Quantity 1 0.43 6 1 - 1 - 1 10-01-2024 Quantity1 Comments: Cro 10-01-2024 Quantity - 1 Comments: Ad	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCl 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal 659981 Description CRI Set-Up edit generated from invoice 658943 659976 Description Biologic Administration ministration for Gilvetmab from 9-19-24 was a second content of the content of	Discount \$0.00 \$0.00 \$870.00 \$0.00 \$0.00 Invoice Discount Invoice Discount Invoice	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 TAX: \$6 \$288.90 Department Primary Inventory SFV Total excluding TAX: \$288.90 Department Primary Inventory SFV Total excluding TAX: \$288.90 TAX: \$6	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00 0.00 Total: \$512.49 Total -\$455.00 0.00 Total: -\$455.00
10-01-2024 Quantity 1 0.43 6 1 10-01-2024 Quantity Comments: Cre 10-01-2024 Quantity	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal 659981 Description CRI Set-Up edit generated from invoice 658943 659976 Description Biologic Administration	Discount \$0.00 \$0.00 \$870.00 \$0.00 \$0.00 Invoice Discount Invoice Discount	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 -\$455.00 Department Primary Inventory SFV Total excluding TAX: -\$455.00 TAX: \$6 \$288.90 Department Primary Inventory SFV	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00 0.00 Total: \$512.49 Total -\$455.00 0.00 Total: -\$455.00
10-01-2024 Quantity 1 0.43 6 1 - 1 - 1 10-01-2024 Quantity1 Comments: Cro 10-01-2024 Quantity - 1 Comments: Ad	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCl 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal 659981 Description CRI Set-Up edit generated from invoice 658943 659976 Description Biologic Administration ministration for Gilvetmab from 9-19-24 was a second content of the content of	Discount \$0.00 \$0.00 \$870.00 \$0.00 \$0.00 Invoice Discount Invoice Discount Invoice	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 TAX: \$6 \$288.90 Department Primary Inventory SFV Total excluding TAX: \$288.90 Department Primary Inventory SFV Total excluding TAX: \$288.90 TAX: \$6	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00 0.00 Total: \$512.49 Total -\$455.00 0.00 Total: -\$455.00
10-01-2024 Quantity 1 0.43 6 1 10-01-2024 Quantity Comments: Cre 10-01-2024 Quantity Comments: Ad	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal 659981 Description CRI Set-Up edit generated from invoice 658943 659976 Description Biologic Administration ministration for Gilvetmab from 9-19-24 vi 659987	Discount \$0.00 \$0.00 \$870.00 \$0.00	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 TAX: \$6 -\$455.00 Department Primary Inventory SFV Total excluding TAX: -\$455.00 TAX: \$6 \$288.90 Department Primary Inventory SFV Total excluding TAX: \$288.90 TAX: \$6 \$40.75	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00 Total: \$512.49 Total -\$455.00 0.00 Total: -\$455.00 Total \$288.90 0.00 Total: \$288.90
10-01-2024 Quantity 1 0.43 6 1 - 1 - 1 10-01-2024 Quantity - 1 Comments: Cre 10-01-2024 Quantity - 1 Comments: Ad 10-01-2024 Quantity	659913 Description Consult, Oncology Recheck Diphenhydramine Inj HCI 50mg/mL (Per mL) Gilvetmab Injectable 20mg/mL (Per mL) Biologic Administration Hazardous Waste Disposal 659981 Description CRI Set-Up edit generated from invoice 658943 659976 Description Biologic Administration ministration for Gilvetmab from 9-19-24 v 659987 Description	Discount \$0.00 \$0.00 \$870.00 \$0.00	\$512.49 Department Primary Inventory SFV Total excluding TAX: \$512.49 TAX: \$6 -\$455.00 Department Primary Inventory SFV Total excluding TAX: -\$455.00 TAX: \$6 \$288.90 Department Primary Inventory SFV Total excluding TAX: \$288.90 TAX: \$6 \$40.75 Department	Total \$126.00 \$43.59 \$0.00 \$288.90 \$54.00 \$126.00 Total: \$512.49 Total -\$455.00 Total: -\$455.00 Total: \$288.90 \$10.00 \$10.00 Total: \$288.90 \$10.00 Total: \$280.00 \$10.00 Total:

10-15-2024	661034	Invoice	\$1682.58	
Quantity	Description	Discount	Department	Total
1	Consult, Oncology Recheck		Primary Inventory SFV	\$126.00
1	CBC		Primary Inventory SFV	\$111.00
1	Blood Collection, Diagnostic		Primary Inventory SFV	\$38.96
1	Pre-surgical Panel		Primary Inventory SFV	\$150.00
6	Gilvetmab Injectable 20mg/mL (Per mL)		Primary Inventory SFV	\$870.00
1	Biologic Administration		Primary Inventory SFV	\$288.90
1	Chemo Hazardous Waste Disposal		Primary Inventory SFV	\$54.00
	Diphenhydramine Inj HCI 50mg/mL (Per		, ,	
0.44	_mL)		Primary Inventory SFV	\$43.72
			Total excluding TAX: \$1682.58 TAX: \$0.00	Total: \$1682.58
10-23-2024	661759	Invoice	\$126.00	
Quantity	Description	Discount	Department	Total
1	Consult, Oncology Recheck		Primary Inventory SFV	\$126.00
			Total excluding TAX: \$126.00 TAX: \$0.00	Total: \$126.00
10-31-2024	662562	Invoice	\$1382.36	T-4-1
Quantity 1	Description	Discount	Department	Total \$126.00
1 1	Consult, Oncology Recheck		Primary Inventory SFV Primary Inventory SFV	
6	Biologic Administration Gilvetmab Injectable 20mg/mL (Per mL)		Primary Inventory SFV	\$288.90 \$870.00
0	Diphenhydramine Inj HCl 50mg/mL (Per III.)		Primary inventory SEV	\$670.00
0.42	mL)		Primary Inventory SFV	\$43.46
1	Chemo Hazardous Waste Disposal		Primary Inventory SFV	\$54.00
			Total excluding TAX: \$1382.36 TAX: \$0.00	Total: \$1382.36
11-14-2024	663631	Invoice	\$349.96	
Quantity	Description	Discount	Department	Total
1	Consult, Oncology Recheck		Primary Inventory SFV	\$126.00
1	Pre-Operative Screen w/SDMA,CBC		Primary Inventory SFV	\$185.00
1	Blood Collection, Diagnostic		Primary Inventory SFV	\$38.96
F			Total excluding TAX: \$349.96 TAX: \$0.00	Total: \$349.96
12-11-2024	665755	Invoice	\$126.00	
Quantity	Description	Discount	Department	Total
1	Consult, Oncology Recheck	Discount	Primary Inventory SFV	\$126.00
- -			Total excluding TAX: \$126.00 TAX: \$0.00	Total: \$126.00
01-08-2025	667908	Invoice	\$446.24	
			\$446.24	
Quantity	Description	Discount	Department	Total
1	Consult, Oncology Recheck		Primary Inventory SFV	\$126.00
1	Pre-Operative Screen w/SDMA,CBC		Primary Inventory SFV	\$196.10
1	Blood Collection, Diagnostic		Primary Inventory SFV	\$38.96
$-\frac{2}{}$	Yunnan Baiyao 250mg 16ct (Per Box)		Primary Inventory SFV	\$85.18 \$85.18
			Total excluding TAX: \$446.24 TAX: \$0.00	Total: \$446.24
01-08-2025	668038	Invoice	\$29.24	
Quantity	Description	Discount	Department	Total
14	Gabapentin 100mg (Per Capsule)		Primary Inventory SFV	\$29.24
			Total excluding TAX: \$29.24 TAX: \$0.00	Total: \$29.24
Payments:				
Date	Ref. No. Cust. Ref.	Transaction Type	Patient Charges Payme	ents Balance
04-09-2024	786377	Payment: Mastercard	\$108	7.11
04-10-2024	786490	Payment: Mastercard	\$70	0.71

Payment: Mastercard

Payment: Mastercard

\$523.81

\$828.00

05-22-2024

06-19-2024

790124

792555

07-10-2024	794162	Payment: Mastercard	\$114.00
07-24-2024	795433	Payment: Mastercard	\$114.00
08-13-2024	797095	Payment: Mastercard	\$490.96
08-20-2024	797693	Payment: Mastercard	\$320.75
08-27-2024	798333	Payment: Mastercard	\$543.31
09-05-2024	799168	Payment: Mastercard	\$2698.76
09-11-2024	799706	Payment: Mastercard	\$275.96
09-19-2024	800466	Payment: Mastercard	\$678.46
10-01-2024	801456	Payment: Mastercard	\$346.39
10-01-2024	801467	Payment: Mastercard	\$40.75
10-15-2024	802669	Payment: Mastercard	\$1682.58
10-23-2024	803363	Payment: Mastercard	\$126.00
10-31-2024	804175	Payment: Visa	\$1382.36
11-14-2024	805404	Payment: Mastercard	\$349.96
12-11-2024	807720	Payment: Mastercard	\$126.00
01-08-2025	810136	Payment: Mastercard	\$446.24
01-08-2025	810175	Payment: Mastercard	\$29.24

Cut on line below and return slip with payment

Please remit with payment

Client Name:	Stephen Winick	Client Number:	401267
	11037 Santa Monica Boulevard		
Address:	Westwood Los Angeles, California, 90025	Balance Due:	\$0.00
		Amount Paid:	



Old fashioned love and all the latest technology.

Veterinary Cancer Group, San Fernando Valley

20051 Ventura Boulevard, Suite I

Suite I

Woodland Hills, California, 91364

Ph: (818) 888-6882 **Fax:** (818) 436-0456

Email: sfv.info@vetcancergroup.com

www.vetcancergroup.com

Invoice#: 645562

Client#: 401267

Client: Stephen Winick

Patient#: Patient: Weight:

192356 Stella 24.0304lbs.

Date: 04-10-2024 Address:

Next Appointment: Stella - 05-08-2024 9:30:00am

Description	Staff Member	Qty	Price	Discount	Discount (%)	Total
Consult, Oncology Recheck	Christine Oakley, DVM, DACVIM	1	\$114.00	\$114.00	100%	\$0.00
CBC - Heska	Christine Oakley, DVM, DACVIM	1	\$92.19	\$92.19	100%	\$0.00
Pre-surgical Panel	Christine Oakley, DVM, DACVIM	1	\$150.00	\$150.00	100%	\$0.00
Blood Collection, Diagnostic	Christine Oakley, DVM, DACVIM	1	\$38.96	\$38.96	100%	\$0.00
Catheterization, Peripheral IV	Christine Oakley, DVM, DACVIM	1	\$118.49			\$118.49
Diphenhydramine Inj HCI 50mg/mL (Per mL)	Christine Oakley, DVM, DACVIM	0.43	\$35.50			\$35.50
Dolorex Inj 10mg/mL C-4 (Per mL)	Christine Oakley, DVM, DACVIM	0.22	\$55.24			\$55.24
Anesthesia, Induction Administration	Christine Oakley, DVM, DACVIM	1	\$109.74			\$109.74
PropoFlo 28 Inj 10mg/mL (Per mL)	Christine Oakley, DVM, DACVIM	1.4	\$45.09			\$45.09
Anesthesia, Isoflurane Admin / min	Christine Oakley, DVM, DACVIM	20	\$192.75			\$192.75
Anesthesia, Monitoring / min	Christine Oakley, DVM, DACVIM	20	\$82.60			\$82.60
Electrochemotherapy Set-Up & Admin	Christine Oakley, DVM, DACVIM	1	\$1500.00	\$1500.00	100%	\$0.00
Bleomycin Inj 15 units (Per Vial)	Christine Oakley, DVM, DACVIM	1	\$291.80	\$291.80	100%	\$0.00
Chemotherapy Administration	Christine Oakley, DVM, DACVIM	1	\$73.63	\$73.63	100%	\$0.00
Intralesional Administration by Doctor	Christine Oakley, DVM, DACVIM	1	\$282.07	\$282.07	100%	\$0.00
Chemo Hazardous Waste Disposal	Christine Oakley, DVM, DACVIM	1	\$42.80	\$42.80	100%	\$0.00
Gabapentin 100mg (Per Capsule)	Christine Oakley, DVM, DACVIM	30	\$32.42			\$32.42
Prednisone 10mg (Per Tablet)	Christine Oakley, DVM, DACVIM	30	\$28.88			\$28.88

Subtotal: \$700.71 Including tax: \$700.71 -\$2585.45 Discount: Total: \$700.71 Mastercard: -700.71

Amount paid: \$700.71

Balance: \$0.00

Thank you for entrusting Veterinary Cancer Group with Stella's care. We have offices throughout Southern California that have complete access to your pet's medical history and records. Please call us any time with any questions, comments, or concerns. *If Stella has a pressure bandage from today's visit, remove it one hour after leaving our clinic.

Payment method:

Payment Policy:

Payment in full is required at the time of check out for all services rendered. If you have pet insurance, please inform the front office personnel and they will instruct you on your insurance's policy. Payment may still be required at time of checkout with your insurance reimbursing you. We do accept all major credit cards, Carecredit and Scratchpay. NOTE: Personal checks are no longer an accepted form of payment.

Cancellation Policy:

Please understand that when you forget your appointment or reschedule with minimal notice, we miss the opportunity to see other patients who need us. Because of this, we require 24 hour notice to reschedule appointments.



Old fashioned love and all the latest technology.

Veterinary Cancer Group, San Fernando Valley

20051 Ventura Boulevard, Suite I Suite I Woodland Hills, California, 91364

Ph: (818) 888-6882 Fax: (818) 436-0456

Email: sfv.info@vetcancergroup.com

Full Medical Records

Date: December 13, 2024

Case Doctor: Christine Oakley, DVM, DACVIM

Phone

310-466-1021

310-466-1677

310-444-0011

MEDICAL RECORDS FOR:

3	Client	Details

Name

Winick, Stephen Address 11037 Santa Monica Boulevard

Westwood

Los Angeles, California,

90025

Patient Details

Name Stella Species Canine (Dog) Breed French Bulldog Brown & White Color

7 years 5 months Age Sex Female Spayed Microchip

Referral Westside Animal Hospital

Wednesday the 11th of December 2024

🔼 Additional Comment

Unfortunately the masses are larger after being on Imatinib for a few weeks. We discussed that I would usually give it around 1 month to assess a response, but I am concerned it will continue to progress on Imatinib. We discussed we could give a 5th dose of Gilvetmab, but considering there was progression after the first 4 doses, I dont think giving a 5th would be necessarily that beneficial. We also discussed switching to chlorambucil, but I am concerned given progression on the other drugs (VBL, Palladia, CCNU) that it will not work. Owner elects to finish out the imatinib but we discussed not refilling it, and likely switching to palliative care.

Health Status

Comments: not obtained - exam only

Physical Exam

Mentation: Bright, alert, responsive

Hydration: Hydrated Mucous Membranes: Pink

CRT:1 sec

Eyes: Eyes clear and bright, pupils normal size, symmetrical, sclera white, no ocular discharge

Ears: No exudate observed, no redness present

Oral Cavity: Teeth are free from excessive tartar, no gingivitis present, no obvious oral masses

Nasal Cavity: No obvious abnormalities observed

*Peripheral Lymph Nodes:Larger R axillary mass (see body map) and multiple right sided SQ masses- all larger from prior.

Cervical:no palpable abnormalities, thyroid slip, lymphadenopathy, or obvious masses

Cardiovascular: Regular rhythm; no murmur detected

Respiratory: Lungs auscultate clear

Abdomen: Abdomen palpates without pain, tenderness or obvious masses

Rectal: Did not perform rectal exam

Urogenital, reproductive: External genitalia appears normal; no mammary masses



Old fashioned love and all the latest technology.

Client: Stephen Winick

Patient: Stella

Species: Canine (Dog)

Breed: French Bulldog

Sex: Female Spayed

Age: 06-15-2017

Musculoskeletal: Normal ambulation

Integument: See body map. Multiple R sided SQ masses- larger. 1 dermal mass on dorsal neck.

Neurologic:Appropriate mentation, coordinated gait, normal limb placement; no obvious deficits: full neurologic exam not performed

Radiation side effects: Not applicable

History

Stella is here today. O she is doing well with her appetite and energy, and is not experiencing any diarrhea or vomiting. However, masses throughout Stella's body have grown significantly in size. O has declined blood work at this time and is only requesting an exam.

Medications: Imatinib Pepcid (SID)

Benadryl 25mg (BID)

Prednisone 10mg (1/2 BID)

Refills: O is unsure

CB # 310-466-1021. CR 12/11

Presenting Problem(s)

Recheck 1 mo body map and BW jc 12/5

Monday the 9th of December 2024

Assessments

MCT grade 2/ high grade, MI=18, incompletely excised

Mass along incision- concern for recurrence while on Palladia

 $Right\ axillary\ SQ\ swelling\ - Recurrent\ post\ excision,\ PD\ on\ VBL\ 9/5/24,\ SD\ on\ CCNU\ 9/11/24,\ PD\ on\ 9/19/24,\ PD\ on\ Gilvetmab$

10/15/24 r/o true vs psuedoprogression

MICROSCOPIC FINDINGS: MASS 1: MAST CELL TUMOR, SUBCUTANEOUS, HIGH

GRADE, WITH EXTENSIVE HEMORRHAGE

Negative predictive factors for survival times of subcutaneous mast cell tumors include mitotic index >4, multinucleated cells and

infiltrative pattern:

Mitotic index (>4 in 10 HPF; yes/no): Yes (13/10 HPF (2.37mm2))

Multinucleated cells (yes/no): No Infiltrative pattern (yes/no): No

Surgical margins: Excision is complete based on evaluated sections.

Lateral: 2.0 mm Deep: 1.2 mm

Angiolymphatic invasion: No



Old fashioned love and all the latest technology. Client: Stephen Winick

Patient: Stella

Species: Canine (Dog)

Breed: French Bulldog

Female Spayed Sex:

Age: 06-15-2017

Ventral abdominal along incision: Suspect local recurrence

MICROSCOPIC FINDINGS: MASS 2: CUTANEOUS MAST CELL TUMOR, HIGH GRADE

(2-TIER), GRADE 2 (PATNAIK)

High / Low Grade: High Patnaik grade: 2

Mitotic count: >20 in 10 HPF(2.37 mm2) Angiolymphatic invasion: None identified

Narrowest histologic Margins: Excision is complete.

Lateral: 0.9 mm

Grade 3 neutropenia post VBL



Body Map

SAO55 (ONLY IF ACCESS DIDN"T DO BW YESTERDAY) - no bw done at ACCESS- OWNER DECLINES TODAY Continue Benadryl, pepcid, Prednisone and Imatinib (had given 1 months worth, but no refills without bloodwork) Recheck 3 wks exam and body map

Tech: SAM/RW

Tuesday the 9th of April 2024



Master Problems

Mast Cell Neoplasm

If you have any questions regarding Stella or any other patients with whom we may be of assistance, please don't hesitate to call.

Sincerely,

The Doctors and Staff of Veterinary Cancer Group



Lake Balboa Veterinary Care

W: (818) 907-0929 - F: (818) 907-0234 http://www.lbvetcare.com

Payment History - Steve Winick

Receipt Number 96874

Payment Entry Date 1/10/2025 9:08 AM

Amount Paid \$25.00

Payment Mastercard \$25.00

Last 4 of Credit Card:

3110

Cashier Gloria X.

 Invoice Number
 93870

 Date
 1/10/2025

Patient	Provider	Description	Date	Quantity	Subtotal	Tax	Total
Stella	Sindy Habib, D.V.M.	Exam, scheduled	1/10/2025	1	\$60.00	\$0.00	\$60.00
Stella	Sindy Habib, D.V.M.	Spot blood glucose	1/10/2025	1	\$25.00	\$0.00	\$25.00
						Subtotal	\$85.00
						Tax	\$0.00
					Inv	oice Total	\$85.00
					Cr	edit Used	(\$60.00)
						Paid	\$25.00
					Pa	id to Date	\$85.00
				Α	mount Re	maining	\$0.00